BOTHELL, WA--(Marketwire - September 08, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12, 2011, at 1:35 p.m. Eastern Time (10:35 a.m. Pacific Time) at The Waldorf-Astoria in New York, NY. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.
A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company’s website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech’s goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Contact:
Marina Biotech, Inc.:
Peter Garcia
Chief Financial Officer
(425) 908-3603
